Clinical Trials Browser

Phase 1/2 × dacomitinib × Thoracic × Clear all

NCT05271916 2023-04-19

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung